Analyst Ratings For Biogen (NASDAQ:BIIB)
Today, Canaccord Genuity raised its price target on Biogen (NASDAQ:BIIB) to $350.00 per share.
Some recent analyst ratings include
- 1/21/2018-Barclays Reiterated Rating of Buy.
- 1/18/2018-Mizuho Reiterated Rating of Buy.
- 1/16/2018-Citigroup Reiterated Rating of Outperform.
- 1/2/2018-Piper Jaffray Companies Reiterated Rating of Buy.
Recent Insider Trading Activity For Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) has insider ownership of 0.25% and institutional ownership of 88.18%.
- On 12/29/2018 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 1/9/2018 Robert W Pangia, Director, sold 5,832 with an average share price of $329.65 per share and the total transaction amounting to $1,922,518.80.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 11/29/2017 Alexander J Denner, Director, bought 30,000 with an average share price of $317.36 per share and the total transaction amounting to $9,520,800.00.
- On 7/25/2017 Susan H Alexander, EVP, sold 4,974 with an average share price of $290.01 per share and the total transaction amounting to $1,442,509.74.
- On 7/19/2017 Susan H Alexander, EVP, sold 7,758 with an average share price of $285.00 per share and the total transaction amounting to $2,211,030.00.
- On 6/9/2017 Brian S Posner, Director, sold 1,084 with an average share price of $256.31 per share and the total transaction amounting to $277,840.04.
Recent Trading Activity for Biogen (NASDAQ:BIIB)
Shares of Biogen closed the previous trading session at 345.10 down -1.65 0.48% with 348.8900146484375 shares trading hands.